ArticleMalaria journal2026
Genetic variation in the Duffy blood group among vivax malaria patients and its impact on disease susceptibility.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
introductionPlasmodium vivax is a widely distributed human malaria parasite in Ethiopia. Known for its ability to form hypnozoites and early gametocytogenesis, it promotes transmission and challenges global elimination efforts. The red blood cell reticulocyte stage is the primary target, and entry is facilitated primarily by the interaction between the Duffy-binding protein (PvDBP) and the Duffy Antigen Receptor for Chemokines (DARC). This study aimed to evaluate genetic variation in the Duffy blood group among P. vivax malaria patients and its effect on illness susceptibility.
methodA facility-based cross-sectional study was carried out between January and June 2024 at four sites, including Arba Minch General Hospital, Dil Fana Primary Hospital, Shecha Health Center, and Weze Health Center in Arba Minch. Molecular screening was performed via SYBR Green qPCR, and Duffy genotyping via a TaqMan-based qPCR assay for 485 microscopy-confirmed P. vivax-infected samples. Demographic and clinical data were stored on an open data kit mobile application and analyzed via SPSS.
resultAmong the 485 samples, 93.8% were mono-P. vivax infections, whereas the remaining 6.2% were mixed P. vivax and P. falciparum infections. Relatively more males (58.4%) aged between 15 and 24 years participated in this study. Almost all the study participants were Duffy positive, with 75.1% (364/485) being heterozygous and 24.5% (119/485) being homozygous. Two of the study participants (0.4%) were Duffy-negative individuals, and both had mixed P. vivax and P. falciparum infections.
conclusionThis study revealed a low prevalence of the Duffy-negative genotype, all of which presented with mixed infections characterized by low parasitemia. This finding indicates that Duffy negativity is not an absolute barrier to P. vivax infection, suggesting the existence of a possible alternative invasion pathway. Further research targeting alternative invasion pathways is recommended to better understand this phenomenon.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.